|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o CuraGen Corp., of Branford, Conn., and TopoTarget A/S, of Copenhagen, Denmark, started a Phase I trial evaluating the administration of oral PXD101, a small-molecule histone deacetylase inhibitor, in patients with advanced solid tumors. The open-label, multicenter trial is designed to establish the maximum tolerated dose for oral PXD101 administered once or twice daily. Patients in the U.S. and Europe will be treated with oral PXD101 in a dose-escalation regimen and may continue to receive up to eight or more treatment cycles depending on disease response. Preliminary results are expected by the end of 2007.
o MGI Pharma Inc., of Minneapolis, said the FDA has ...
Related newspaper, magazine, and journal articles:
|
|
Article: MGI PHARMA and SuperGen Announce Signing of a ...
Business Wire;
September 1, 2004 ;
700+ words
... ... MINNEAPOLIS & DUBLIN, Calif. -- MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen ... signed a definitive agreement granting MGI PHARMA exclusive worldwide rights to the development ... Under the terms of this agreement, MGI PHARMA will make a $40 million equity investment ...
|
|